Neue Therapiekonzepte für die Herzinsuffizienz: Studien-Highlights 2020

It is to be feared that the great vulnerability of patients with cardiovascular diseases to the coronavirus disease 2019 (COVID-19) pandemic will further heighten the already enormous burden of morbidity and mortality of heart failure. Many of the clinical trials published in 2020 show the favorable...

Descripción completa

Detalles Bibliográficos
Autores principales: Birner, Christoph, Laufs, Ulrich, Frey, Norbert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Medizin 2021
Materias:
Schwerpunkt
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903396/
http://dx.doi.org/10.1007/s12181-021-00446-z
Descripción
Sumario:It is to be feared that the great vulnerability of patients with cardiovascular diseases to the coronavirus disease 2019 (COVID-19) pandemic will further heighten the already enormous burden of morbidity and mortality of heart failure. Many of the clinical trials published in 2020 show the favorable effects of innovative treatment principles. For the treatment of systolic heart insufficiency (heart failure with reduced ejection fraction, HFrEF) sodium-glucose cotransporter 2 (SGLT2) inhibitors and sacubitril/valsartan are prioritized.

Ejemplares similares